Monday, 27 August, 2007



Current: 360 Target : 575 in 6 months

I would like to update you with the latest news on Ranbaxy.

* On 22nd August 07, Ranbaxy Laboratories Limited, India's biggest pharma company, launched its ureological drug Roliflo OD in India. Roliflo is a combination of Tamsulosin and Tolterodine. Roliflo is a Novel Drig Delivery Syste product which is being introduced for the first time in India.

* According to CNBC, the pharmaceuticals market will rise by 20% in India. Pharma industry will expectedly be worth Rs.20 billion in next 3 years including exports.

* On 20th August, Ranbaxy Laboratories Limited (RLL), announced that the Company has received approval from the U.S. Food and Drug Administration to manufacture and market Hydrocodone Bitartrate and Acetaminophen Tablets USP. The Office of Generic Drugs, U.S. Food and Drug Administration, has determined the Ranbaxy formulations to be bioequivalent and have the same therapeutic effect as that of the reference listed drugs. Total annual market sales for Hydrocodone Bitartrate and Acetaminophen Tablets were $390.6 million (IMS – MAT: June 2007). Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the relief of moderate to moderately severe pain. According to Jim Meehan, Vice President of Sales and Marketing for RPI Ranbaxy received final FDA approval for multiple strengths of this product. These approvals further expand their product portfolio of affordable generic alternatives and will be launched in a November 2007 time period to all classes of trade.

* US Patent and Trademark Office rejected Pfizer's application to re-issue a patent, which extends Pfizer's patent rights over Lipitor to June 2011.
Ranbaxy may launch the generic version of Pfizer's largest-selling cholesterol-lowering drug, Lipitor, in March 2010, about 15 months ahead of schedule, in the US market.The chances of Ranbaxy eating into the $8.5 billion market of Lipitor in the US brightened .Being the holder of 180-day exclusive marketing rights for atorvastatin (the generic name of Lipitor), Ranbaxy is likely to be the biggest beneficiary of the decision.